Intensive postgrafting immune suppression combined with nonmyeloablative conditioning for transplantation of HLA-identical hematopoietic cell grafts: results of a pilot study for treatment of primary immunodeficiency disorders

[1]  P. Martin.  Documentation of Engraftment and Characterization of Chimerism Following Hematopoietic Cell Transplantation , 2009 .

[2]  J. Sanders.  Growth and Development After Hematopoietic Cell Transplantation , 2009 .

[3]  L. Notarangelo,et al.  Primary immunodeficiency diseases , 2008 .

[4]  S. Davies,et al.  Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. , 2007, Blood.

[5]  M. Maris,et al.  Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  R. Storb,et al.  Extending Postgrafting Cyclosporine Decreases the Risk of Severe Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation , 2006, Transplantation.

[7]  M. Maris,et al.  Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. , 2005, Blood.

[8]  R. Storb,et al.  Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long‐term follow‐up , 2005, British journal of haematology.

[9]  M. Maris,et al.  Prognostic relevance of ‘early‐onset’ graft‐versus‐host disease following non‐myeloablative haematopoietic cell transplantation , 2005, British journal of haematology.

[10]  H. Ochs,et al.  Molecular analysis of a large cohort of patients with the hyper immunoglobulin M (IgM) syndrome. , 2005, Blood.

[11]  F. Appelbaum,et al.  Final adult height of patients who received hematopoietic cell transplantation in childhood. , 2005, Blood.

[12]  P. Veys,et al.  Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. , 2005, Blood.

[13]  M. Maris,et al.  Prognostic Relevance of “Early-Onset” Graft-Versus-Host Disease Following Nonmyeloablative Hematopoietic Cell Transplantation. , 2004 .

[14]  J. Sanders.  Endocrine complications of high‐dose therapy with stem cell transplantation , 2004, Pediatric transplantation.

[15]  Anajane G. Smith,et al.  Ten HLA-DR4 alleles defined by sequence polymorphisms within the DRB1 first domain , 2004, Immunogenetics.

[16]  F. Appelbaum,et al.  Thomas' hematopoietic cell transplantation , 2003 .

[17]  S. Heimfeld,et al.  HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. , 2003, Blood.

[18]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[19]  M. Maris,et al.  Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. , 2003, Blood.

[20]  R. Storb,et al.  Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio , 2003, Blood.

[21]  N. Schmitz,et al.  Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. , 2002, Blood.

[22]  H. Deeg,et al.  Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. , 2002, Blood.

[23]  Noel R. Rose,et al.  Manual of clinical laboratory immunology , 2002 .

[24]  M. Zaniew,et al.  Increased apoptosis of peripheral blood lymphocytes in children with nephrotic syndrome , 2002, Pediatric Nephrology.

[25]  J. Radich,et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.

[26]  S. Holland,et al.  Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. , 2001, The New England journal of medicine.

[27]  J. V. Stone,et al.  Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. , 2001, Blood.

[28]  A. Limaye,et al.  Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients. , 2001, The Journal of infectious diseases.

[29]  R Storb,et al.  Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. , 2001, The New England journal of medicine.

[30]  G. Mieli-Vergani,et al.  Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. , 2000, Blood.

[31]  J. Hansen,et al.  Increased Apoptosis of Peripheral Blood T Cells following Allogeneic Hematopoietic Cell Transplantation , 2022 .

[32]  J. Bourhis,et al.  Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. Limaye,et al.  Detection of Epstein-Barr Virus DNA in Sera from Transplant Recipients with Lymphoproliferative Disorders , 1999, Journal of Clinical Microbiology.

[34]  Anajane G. Smith,et al.  Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. , 1998, Blood.

[35]  M. Helbert,et al.  A simple flow cytometry assay using dihydrorhodamine for the measurement of the neutrophil respiratory burst in whole blood: comparison with the quantitative nitrobluetetrazolium test. , 1998, Journal of immunological methods.

[36]  H. Deeg,et al.  Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. , 1997, Blood.

[37]  M. Boeckh,et al.  Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. , 1996, Blood.

[38]  A. Filipovich.  STEM CELL TRANSPLANTATION FROM UNRELATED DONORS FOR CORRECTION OF PRIMARY IMMUNODEFICIENCIES , 1996, Radiologic Clinics of North America.

[39]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[40]  C. McFarland,et al.  Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers. , 1995, Blood.

[41]  A. Fischer,et al.  A primary T-cell immunodeficiency associated with defective transmembrane calcium influx. , 1995, Blood.

[42]  W. Friedrich,et al.  Bone marrow transplantation (BMT) in Europe for primary immunodeficiencies other than severe combined immunodeficiency: a report from the European Group for BMT and the European Group for Immunodeficiency , 1994 .

[43]  M. Loken,et al.  CD45 Gating for Routine Flow Cytometric Analysis of Human Bone Marrow Specimens , 1993, Annals of the New York Academy of Sciences.

[44]  A. Filipovich.  Bone marrow transplantation from unrelated donors for congenital immunodeficiencies. , 1993, Bone marrow transplantation.

[45]  J. L. Goodman,et al.  A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. , 1992, The New England journal of medicine.

[46]  D. Green,et al.  Late effects of treatment for childhood cancer , 1992 .

[47]  K. Sullivan,et al.  Chronic graft-versus-host disease and other late complications of bone marrow transplantation. , 1991, Seminars in hematology.

[48]  A. Fischer,et al.  European experience of bone-marrow transplantation for severe combined immunodeficiency , 1990, The Lancet.

[49]  Y. Nakamura,et al.  Amplification of a variable number of tandem repeats (VNTR) locus (pMCT118) by the polymerase chain reaction (PCR) and its application to forensic science. , 1990, Journal of forensic sciences.

[50]  E. Boerwinkle,et al.  Rapid typing of tandemly repeated hypervariable loci by the polymerase chain reaction: application to the apolipoprotein B 3' hypervariable region. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[51]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[52]  J. Henry.  Clinical diagnosis and management by laboratory methods , 1979 .

[53]  H. Ochs,et al.  Does graft-versus-host disease influence the tempo of immunologic recovery after allogeneic human marrow transplantation? An observation on 56 long-term survivors. , 1978, Blood.

[54]  R Storb,et al.  Bone-marrow transplantation (first of two parts). , 1975, The New England journal of medicine.

[55]  H. Ochs,et al.  Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases. , 1971, The Journal of clinical investigation.

[56]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .